Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial.

efimosfermin alfa (GSK6519754) - GSK

http://www.ncbi.nlm.nih.gov/pubmed/41655584

Brenda Jeglinski; Gerard Bain; Jeff Zhao; Kris V Kowdley; Margaret James Koziel; Mazen Noureddin; Rohit Loomba; Tatjana Odrljin

Feb 9, 2026